Skip to main content

Advertisement

SpringerLink
Log in

Modeling and simulation of adherence: Approaches and applications in therapeutics

  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

Partial adherence with a prescribed or randomly assigned dose gives rise to unintended variability in actual drug exposure in clinical practice and during clinical trials. There are tremendous costs associated with incomplete and/or improper drug intake—to both individual patients and society as a whole. Methodology for quantifying the relation between adherence, exposure and drug response is an area of active research. Modeling and statistical approaches have been useful in evaluating the impact of adherence on therapeutics and in addressing the challenges of confounding and measurement error which arise in this context. This paper reviews quantitative approaches to using adherence information in improving therapeutics. It draws heavily on applications in the area of HIV pharmacology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vrijens B, Tousset E, Gaillard P, Metry J, Urquhart J. Major features of dose omissions in 87 ambulatory drug trials.Clin Pharmacol Ther. 2005;77:P99.

    Google Scholar 

  2. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance.Am J Hosp Pharm. 1991;48:1978–1988.

    PubMed  CAS  Google Scholar 

  3. Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press Ltd; 1991.

    Google Scholar 

  4. Didlake RH, Dreyfus K, Kermanet RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants.Transplant Proc. 1988;20(suppl 3):63–69.

    PubMed  CAS  Google Scholar 

  5. Kastrissios H, Blaschke TF. Therapeutic implications of nonadherence with antiretroviral drug regimens.HIV. 1998;8:24–28.

    Google Scholar 

  6. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens.Postgrad Med J. 1992;68(suppl 3):S49-S59.

    PubMed  Google Scholar 

  7. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy.Clin Pharmacokinet. 1997;32:345–356.

    PubMed  CAS  Google Scholar 

  8. Hong JH, Sumrani N, Delaney V, et al. Causes of late renal allograft failure in the ciclosporin era.Nephron. 1992;62:272–279.

    PubMed  CAS  Google Scholar 

  9. Dunn J, Golden D, Van Buren CT, et al. Causes of graft loss beyond two years in the cyclosporine era.Transplantation. 1990;49:349–353.

    PubMed  CAS  Google Scholar 

  10. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research.Clin Pharmacokinet. 1994;27:202–215.

    Article  PubMed  CAS  Google Scholar 

  11. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care.J Clin Epidemiol. 1997;50:385–391.

    Article  PubMed  CAS  Google Scholar 

  12. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique.JAMA. 1989;261:3273–3277.

    Article  PubMed  CAS  Google Scholar 

  13. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.Pharmacoeconomics. 1999;15:423–434.

    Article  PubMed  CAS  Google Scholar 

  14. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.N Engl J Med. 1994;330:1179–1184.

    Article  PubMed  CAS  Google Scholar 

  15. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice.Clin Ther. 1999;21:1074–1090.

    Article  PubMed  CAS  Google Scholar 

  16. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).AIDS Care. 2000;12: 255–266.

    Article  PubMed  CAS  Google Scholar 

  17. de Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device.Br J Rheumatol. 1996;35:60–65.

    Article  PubMed  Google Scholar 

  18. Lee JY, Kusek JW, Greene PF, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.Am J Hypertens. 1996;9:719–725.

    Article  PubMed  CAS  Google Scholar 

  19. Bloch M, Gur E, Shalev AY. Hypouricemic effect of zuclopenthixol: a potential marker of drug compliance?Psychopharmacology (Berl). 1992;109:377–378.

    Article  CAS  Google Scholar 

  20. Kapur S, Ganguli R, Ulrich R, et al. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics.Schizophr Res. 1991;6:49–53.

    Article  PubMed  CAS  Google Scholar 

  21. Hardy E, Kumar S, Peaker S, et al. A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release ‘therapeutic drug’ (metoprolol, Metoros) in reflecting incomplete compliance by volunteers.Br J Clin Pharmacol. 1990;30:437–441.

    PubMed  CAS  Google Scholar 

  22. Maenpaa H, Javela K, Pikkarainen JH, et al. Minimal doses of digoxin: a new marker for compliance to medication.Eur Heart J. 1987;8(suppl 1):31–37.

    PubMed  Google Scholar 

  23. Pekovic V, Mayanja H, Vjecha M, et al. Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration.J Clin Epidemiol. 1998;51:597–607.

    Article  PubMed  CAS  Google Scholar 

  24. Lu J, Gries JM, Verotta D, et al. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.J Pharmacokinet Pharmacodyn. 2001;28:343–362.

    Article  PubMed  CAS  Google Scholar 

  25. Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients with HIV infection: a comparison of two measurement methods.AIDS Read. 1999;9:329–338.

    PubMed  CAS  Google Scholar 

  26. Carroll RJ, Ruppert D, Stefanski LA. Measurement error in nonlinear models. Boca Raton, FL: CRC Press, 1998.

    Google Scholar 

  27. Kenna LA, Sheiner LB. Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods.Stat Med. 2004;23:3561–3580.

    Article  PubMed  Google Scholar 

  28. Kenna LA. Estimating treatment effect in the presence of non-compliance measured with error: power, precision and robustness of data analysis methods [dissertation].PhD Thesis. San Francisco, CA; University of California San Francisco: 2001.

    Google Scholar 

  29. Catania JA, Binson D, Canchola J, et al. Effects of interviewer gender, interviewer choice, and item wording on response to questions concerning sexual behavior.Public Opinion Quarterly. 1996;60:345–375.

    Article  Google Scholar 

  30. Kaplan RM, Simon HJ. Compliance in medical care: reconsideration of self-predictions.Ann Behav Med. 1990;12:66–71.

    Article  Google Scholar 

  31. Hyland ME, Kenyon CA, Allen R, et al. Diary keeping in asthma: comparison of written and electronic methods.BMJ. 1993;306:487–489.

    PubMed  CAS  Google Scholar 

  32. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.AIDS. 2000;14:357–366.

    Article  PubMed  CAS  Google Scholar 

  33. Feinstein AR. On white-coat effects and the electronic monitoring of compliance.Arch Intern Med. 1990;150:1377–1378.

    Article  PubMed  CAS  Google Scholar 

  34. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors.Ann Intern Med. 2001;134:968–977.

    PubMed  CAS  Google Scholar 

  35. Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments.Control Clin Trials. 1997;18:187–203.

    Article  PubMed  CAS  Google Scholar 

  36. Robins JM. Correction for non-compliance in equivalence trials.Stat Med. 1998;17:269–302; discussion 387–389.

    Article  PubMed  CAS  Google Scholar 

  37. Goetghebeur E, Molenberghs G, Katz J. Estimating the causal effect of compliance on binary outcome in randomized controlled trials.Stat Med. 1998;17:341–355.

    Article  PubMed  CAS  Google Scholar 

  38. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials.J Am Stat Assoc. 1991;86:9–22.

    Article  Google Scholar 

  39. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials.Clin Pharmacol Ther. 1995;57:6–15.

    Article  PubMed  CAS  Google Scholar 

  40. Angrist JD, Imbens GW, Rubin DR. Identification of causal effects using instrumental variables.J Am Stat Assoc. 1996;91:444–472.

    Article  Google Scholar 

  41. Albert JM, Demets DL. On a model-based approach to estimating efficacy in clinical trials.Stat Med. 1994;13:2323–2335.

    Article  PubMed  CAS  Google Scholar 

  42. Jonsson EN, Wade JR, Almqvist G, et al. Discrimination between rival dosing histories.Pharm Res. 1997;14:984–991.

    Article  PubMed  CAS  Google Scholar 

  43. Cheng CW, Woo KS, Chan JC, et al. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease.Br J Clin Pharmacol. 2004;58:528–535.

    Article  PubMed  Google Scholar 

  44. Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.Am J Med. 2002;113:625–629.

    Article  PubMed  CAS  Google Scholar 

  45. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs.Med J Aust. 1996;164:208–211.

    PubMed  CAS  Google Scholar 

  46. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care.Am J Manag Care. 1999;5:437–444.

    PubMed  CAS  Google Scholar 

  47. Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: compliance study 1993–1998.Br J Clin Pharmacol. 2002;53:375–378.

    Article  PubMed  Google Scholar 

  48. Hughes DA, Walley T. Predicting “real world” effectiveness by integrating adherence with pharmacodynamic modeling.Clin Pharmacol Ther. 2003;74:1–8.

    Article  PubMed  CAS  Google Scholar 

  49. Williams-Deane M, Potter LS. Current oral contraceptive use instructions: An analysis of patient package inserts.Fam Plann Perspect. 1992;24:111–115.

    Article  PubMed  CAS  Google Scholar 

  50. Urquhar J. Erratic patient compliance with prescribed drug regiments: target for drug delivery systems.Clin Pharmacol Ther. 2000;67:331–334.

    Article  Google Scholar 

  51. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness.Heart. 2002;88:203–206.

    Article  PubMed  Google Scholar 

  52. Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs.Am J Ther. 1994;1:260–267.

    Article  PubMed  Google Scholar 

  53. Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol.Br J Clin Pharmacol. 1982;13(suppl 2):345S-351S.

    PubMed  CAS  Google Scholar 

  54. Vaur L, Dutrey-Dupagne C, Boussac J, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients.J Cardiovasc Pharmacol. 1995;26:127–131.

    Article  PubMed  CAS  Google Scholar 

  55. Leenen FH, Fourney A, Notman G, et al. Persistence of antihypertensive effect after ‘missed doses’ of calcium antagonist with long (amlodipine) vs short (diltiazem), elimination half-life.Br J Clin Pharmacol. 1996;41:83–88.

    PubMed  CAS  Google Scholar 

  56. Mallion JM, Meilhac B, Tremel F, et al. Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment.J Cardiovasc Pharmacol. 1992;19(suppl 2):S41-S48.

    PubMed  Google Scholar 

  57. Lee SY, Song XY. Bayesian analysis of structural equation models with dichotomous variables.Stat Med. 2003;22:3073–3088.

    Article  PubMed  Google Scholar 

  58. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance.JAMA. 1998;279:1997–1983.

    Article  Google Scholar 

  59. Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy.JAMA. 1996;276:1955–1956.

    Article  PubMed  CAS  Google Scholar 

  60. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel.JAMA. 1998;279:1984–1991.

    Article  PubMed  CAS  Google Scholar 

  61. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations.AIDS. 2003;17:1925–1932.

    Article  PubMed  Google Scholar 

  62. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Antimicrob Agents Chemother. 2003;47:130–137.

    Article  PubMed  CAS  Google Scholar 

  63. Urquhart J. Non-compliance: the ultimate absorption barrier. In: Prescott LF, Nimmo WS, eds. Novel Drug Delivery and Its Therapeutic Applications, Chichester, UK: John Wiley & Sons, 1989;127–137.

    Google Scholar 

  64. Kastrissios H, Suarez JR, Katzenstein D, et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.AIDS. 1998;12:2295–2303.

    Article  PubMed  CAS  Google Scholar 

  65. Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis?J Pharmacokinet Biopharm. 1996;24:265–282.

    Article  PubMed  CAS  Google Scholar 

  66. Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance.Stat Med. 1998;17:2313–2333.

    Article  PubMed  CAS  Google Scholar 

  67. Vrijens B. Analyzing time-varying patterns of human exposure to xenobiotics and their biomedical impact. Ghent, Belgium: University of Ghent; 2002.

    Google Scholar 

  68. Labbé L, Hammer SM, Mellors JW, et al. A Markov model for the effect of covariates including drug adherence on longitudinal viral response in HIV patients.Clin Pharmacol Ther. 2004;75:P90.

    Google Scholar 

  69. Labbé L, Verotta D. A non-linear mixed effect dynamic model using adherence to treatment to describe long-term therapy outcome in HIV-patients.Clin Pharmacol Ther. 2005;77:P90.

    Article  CAS  Google Scholar 

  70. Diggle P, Kenward MG. Informative drop-out in longitudinal data analysis.Appl Stats. 1994;43:49–93.

    Article  Google Scholar 

  71. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout.J Pharmacokinet Pharmacodyn. 2003;30:83–103.

    Article  PubMed  Google Scholar 

  72. Noordmohamed SE, Henry WK, Rhame FS, et al. Strategies for control of zidovudine concentrations in serum.Antimicrob Agents Chemother. 1995;39:2792–2797.

    Google Scholar 

  73. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.Am J Med. 2003;115:632–641.

    Article  PubMed  Google Scholar 

  74. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.Ann Intern Med. 1999;131:81–87.

    PubMed  CAS  Google Scholar 

  75. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in “revolving door” schizophrenic patients.J Clin Psychiatry. 1996;57:337–345.

    PubMed  CAS  Google Scholar 

  76. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits.Arch Intern Med. 1990;150:1509–1510.

    Article  PubMed  CAS  Google Scholar 

  77. Waeber B, Leonetti G, Kolloch R, et al. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study.J Hypertens. 1999;17:1041–1045.

    Article  PubMed  CAS  Google Scholar 

  78. Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development.Annu Rev Pharmacol Toxicol. 1997;37:451–475.

    Article  PubMed  CAS  Google Scholar 

  79. Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment.Am J Ophthalmol. 1986;101:515–523.

    PubMed  CAS  Google Scholar 

  80. Peck CC. Non-compliance and clinical trials: regulatory perspectives. In: Metry JM, Meyer UA, eds. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester, UK: John Wiley & Sons, 1999;97–102.

    Google Scholar 

  81. Hasford J. Design and analysis of clinical trials of compliance, In: Metry JM, Meyer UA, eds. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester, UK: John Wiley & Sons, 1999;23–40.

    Google Scholar 

  82. Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients to follow prescriptions for medications.Cochrane Database Syst Rev. 2000;2:CD000011.

    PubMed  Google Scholar 

  83. Volmink J, Garner P. Directly observed therapy for treating tuberculosis.Cochrane Database Syst Rev. 2001;4:CD003343.

    PubMed  Google Scholar 

  84. Barker J, Millard J. Directly observed therapy and treatment adherence.Lancet. 2000;356:1030–1; author reply 1032.

    Article  PubMed  CAS  Google Scholar 

  85. Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals.Drug Info J. 1998;22:363–378.

    Google Scholar 

  86. Sheiner LB. Learning versus confirming in clinical drug development.Clin Pharmacol Ther. 1997;61:275–291.

    Article  PubMed  CAS  Google Scholar 

  87. Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them.Basic Clin Pharmacol Toxicol. 2005;96:228–234.

    Article  PubMed  CAS  Google Scholar 

  88. Lasagn L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, eds. Compliance in Medical Practice and Clinical Trials, JA. New York: Raven Press, 1991;393–403.

    Google Scholar 

  89. Morris SE, Groom GV, Cameron ED, et al. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill (‘Microgynon 30’) omission.Contraception. 1979;20:61–69.

    Article  PubMed  CAS  Google Scholar 

  90. Chowdhury V, Joshi UM, Gopalkrishna K, et al. ‘Escape’ ovulation in women due to the missing of low dose combination oral contraceptive pills.Contraception. 1980;22:241–247.

    Article  PubMed  CAS  Google Scholar 

  91. Wang E, Shi S, Cekan SZ, et al. Hormonal consequences of “missing the pill”.Contraception. 1982;26: 545–566.

    Article  PubMed  CAS  Google Scholar 

  92. Landgren BM, Diczfalusy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.Contraception. 1984;29:437–446.

    Article  PubMed  CAS  Google Scholar 

  93. Landgren BM, Csemiczky G. The effect of follicular growth and luteal function of “missing the pill”. A comparison between a monophasic and a triphasic combined oral contraceptive.Contraception. 1991;43:149–159.

    Article  PubMed  CAS  Google Scholar 

  94. Cross JT, Lee HD, Nelson JS, et al. One in five marketed drugs undergoes a dosage change: 1980–1999.Clin Pharmacol Ther. 2001;69:P63.

    Google Scholar 

  95. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA. 1998;279:1200–1205.

    Article  PubMed  CAS  Google Scholar 

  96. Fremont-Smith K, Kravitz GR, Bush T, et al. Adverse drug reactions in hospitalized patients.J Am Stat Assoc. 1998;280:1741.

    CAS  Google Scholar 

  97. Burney KD, Krishnan K, Ruffin MT, et al. Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring.Arch Farm Med. 1996;5:297–300.

    Article  CAS  Google Scholar 

  98. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications.Ann Intern Med. 2001;134:1004–1006.

    PubMed  CAS  Google Scholar 

  99. Meredith PA, Elliott HL. Therapeutic coverage: reducing the risks of partial compliance.Br J Clin Pract. 1994;73(suppl):13–17.

    CAS  Google Scholar 

  100. Detry JM. Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Compliance.Clin Cardiol. 1994;17(suppl 3):III12-III16.

    PubMed  CAS  Google Scholar 

  101. Urquhart J, De Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens.Stat Med. 1998;17:251–267; discussion 387–389.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Food and Drug Administration, 20857, Rockville, MD

    Leslie A. Kenna

  2. Faculty of Pharmacy, University of Montreal, H3T1J4, Montreal, Quebec, Canada

    Line Labbé

  3. Children's Hospital of Philadelphia, 19104, Philadelphia, PA

    Jeffrey S. Barrett

  4. Strategic Modeling and Simulation, Bristol Myers Squibb, 08543, Princeton, NJ

    Marc Pfister

Authors
  1. Leslie A. Kenna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Line Labbé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey S. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leslie A. Kenna.

Additional information

Published: October 5, 2005

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kenna, L.A., Labbé, L., Barrett, J.S. et al. Modeling and simulation of adherence: Approaches and applications in therapeutics. AAPS J 7, 40 (2005). https://doi.org/10.1208/aapsj070240

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/aapsj070240

Keywords

Search

Navigation